Maven Securities’s Sanara MedTech SMTI Stock Holding History

Maven Securities’s Portfolio SMTI Stock Details SMTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-70,000	Closed	-$2.03M	–	1305
2021 Q1	$2.03M	Buy	+70,000	New	+$2.43M	0.09%	219

Other funds holding SMTI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

NRC

North Run Capital Boston, Massachusetts $43.5M AUM 38.24% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

SIC

Salem Investment Counselors Winston Salem, North Carolina $4.03B AUM 61.49% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Maven Securities's SMTI Position: Q2 2021 in Review

Maven Securities sold out of Sanara MedTech (SMTI) in Q2 2021, closing a stake of 70,000 shares — an estimated $2.03M sold.

Maven Securities first reported a position in SMTI in Q1 2021 and held it in 1 quarter. The position peaked at $2.03M in Q1 2021. 21 funds tracked by Wall St. Rank hold SMTI as of Q2 2021.

Maven Securities reported no remaining Sanara MedTech position as of Q2 2021 after selling out during the quarter.
Maven Securities sold 70,000 Sanara MedTech shares in Q2 2021, an estimated $2.03M.
Maven Securities first reported a position in Sanara MedTech in Q1 2021 and held it in 1 quarter.
Maven Securities's Sanara MedTech position peaked at $2.03M in Q1 2021.
21 funds tracked by Wall St. Rank held Sanara MedTech as of Q2 2021.

Based on Maven Securities's 13F filing for Q2 2021, filed 16 Aug 2021.